Patients undergoing PCI with chronic kidney disease stage 3-5 (non-dialysis) with estimated glomerular filtration rate (eGFR) below than 60 mL/min/1.73 m2 measured by CKD-EPI method Contrast-induced acute kidney injury, Oxidative stress, Mitochondria, Prevention, Melatonin
Conditions
Interventions
Melatonin slow release 10 mg (Natrol, Natrol LLC, USA) will be started at the dose of 10 mg twice a day orally at 48 hours prior to PCI and continue up to 72 hours after PCI in totally 6 doses if they
Active Comparator Drug,Placebo Comparator Drug
Sponsors
Cardiac Electrophysiology Research and Training Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age more than 18 years old 2. Undergoing PCI 3. CKD stage 3-5 (non-dialysis) with estimated glomerular filtration rate (eGFR) below than 60 mL/min/1.73 m2 measured by CKD-EPI method
Exclusion criteria
Exclusion criteria: - ESRD on long term renal replacement therapy - AKI with renal replacement therapy - Receiving contrast media within 5 days - Acute coronary syndrome within 5 days - Acute decompensated heart failure - Life-threatening cardiac arrhythmia (including ventricular tachycardia and ventricular fibrillation) - Cardiac arrest - Cardiogenic shock - Sepsis or septic shock - Active malignancy - Volume of contrast in mL <3 times of eGFR - Lupus nephritis - Autosomal dominant polycystic kidney disease - Severe anemia with hemoglobin <7 mg/dL - Prior treatment with melatonin and other antioxidants; such as vitamin C, curcumin, and herbal medicine; in past 5 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of CI-AKI 7 days after intervention Chi squre test | — |
Secondary
| Measure | Time frame |
|---|---|
| Oxidative stress 7 days after end of the intervention Mitochondrial antioxidant and oxidative stress | — |
Countries
Thailand
Contacts
Public ContactPrit Kusirisin
Chiang Mai University
Outcome results
None listed